Drug delivery to the brain: How can nanoencapsulated statins be used in the clinic?

Sonvico, F; Zimetti, F; Pohlmann, AR; Guterres, SS

Drug delivery to the brain: How can nanoencapsulated statins be used in the clinic?

Sonvico, F

Zimetti, F Pohlmann, AR Guterres, SS

Permalink

Publication Type:: Journal Article
Citation:: Therapeutic Delivery, 2017, 8 (8), pp. 625 - 631
Issue Date:: 2017-07-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Submitted VersionAdobe PDF (303.7 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sonvico, F https://orcid.org/0000-0001-7372-1456	en_US
dc.contributor.author	Zimetti, F	en_US
dc.contributor.author	Pohlmann, AR	en_US
dc.contributor.author	Guterres, SS	en_US
dc.date.available	2020-05-25T19:23:04Z
dc.date.issued	2017-07-01	en_US
dc.identifier.citation	Therapeutic Delivery, 2017, 8 (8), pp. 625 - 631	en_US
dc.identifier.issn	2041-5990	en_US
dc.identifier.uri	http://hdl.handle.net/10453/114789
dc.description.abstract	© 2017 Future Science Ltd. Statins are used for the primary and secondary prevention of cardiovascular disease by inhibiting cholesterol synthesis in the liver. Statins have also noncholesterol-related effects, called pleiotropic effects, which arise from statins' anti-inflammatory, immunomodulatory and antioxidant properties. These effects are especially attractive for the treatment of various brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain concentrations after oral drug administration hinder the clinical application of statins in these pathologies. Pharmaceutical nanotechnologies may offer a solution to this problem, as local or targeted delivery of nanoencapsulated statins may increase brain availability. This special report rapidly summarizes the potential of statins in the treatment of brain diseases and the pharmaceutical nanotechnologies that could provide a viable approach to enable these indications.	en_US
dc.relation.ispartof	Therapeutic Delivery	en_US
dc.relation.isbasedon	10.4155/tde-2017-0044	en_US
dc.subject.mesh	Brain	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Brain Diseases	en_US
dc.subject.mesh	Hydroxymethylglutaryl-CoA Reductase Inhibitors	en_US
dc.subject.mesh	Drug Delivery Systems	en_US
dc.subject.mesh	Nanoparticles	en_US
dc.title	Drug delivery to the brain: How can nanoencapsulated statins be used in the clinic?	en_US
dc.type	Journal Article
utslib.citation.volume	8	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
utslib.for	1109 Neurosciences	en_US
utslib.for	0903 Biomedical Engineering	en_US
utslib.for	1004 Medical Biotechnology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	open_access
pubs.issue	8	en_US
pubs.publication-status	Published	en_US
pubs.volume	8	en_US

Abstract:

© 2017 Future Science Ltd. Statins are used for the primary and secondary prevention of cardiovascular disease by inhibiting cholesterol synthesis in the liver. Statins have also noncholesterol-related effects, called pleiotropic effects, which arise from statins' anti-inflammatory, immunomodulatory and antioxidant properties. These effects are especially attractive for the treatment of various brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain concentrations after oral drug administration hinder the clinical application of statins in these pathologies. Pharmaceutical nanotechnologies may offer a solution to this problem, as local or targeted delivery of nanoencapsulated statins may increase brain availability. This special report rapidly summarizes the potential of statins in the treatment of brain diseases and the pharmaceutical nanotechnologies that could provide a viable approach to enable these indications.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/114789